Although the pharma industry has been relatively slow in its uptake, this began to change in 2017. It has definitely turned in the past year, and we are now seeing a far greater confidence in what data analytics and technology can do for a company’s operations.”

Jonathan Retano

FOUNDER AND CEO, PHARMAFUSION

April 01, 2019

Pharmafusion’s mission is to simplify analytics for the biopharmaceutical value chain. What was the reason behind the conception of Pharmafusion?

Pharmafusion was conceived through an understanding of the needs of pharmaceutical industry leaders and my knowledge of data management and analytics. We envisioned Pharmafusion as a platform that could provide a fully packaged experience to the user to address the frequent pain-points of pharmaceutical commercial operations. Subsequently, we developed a turnkey platform that has all the datasets for pharmaceutical analytics one requires – all on one platform. The key was to make pharma analytics as easy as watching smart TV and to flip the Pareto 80-20, which we were successful in doing.  As a result, companies can now spend more time on value-add work, such as strategy that is really going to drive their business forward rather than gathering and organizing data as this is carried out by our platform.

Could you elaborate on your award-winning Pharmafusion platforms?

We have a number of different solutions at Pharmafusion that we use to help facilitate a streamlined analytics process for our customers. SpydeRx, for example is used to monitor competitor activity in all drug classes through a daily notification of price changes, new entrants and FDA filings. Pharmafusion 360 is our award-winning, enterprise-wide data warehouse and business analytics platform that was designed for commercial pharmaceutical operations.

Our philosophy was to easily pivot the platform so it can be used in-house. For a small company that does not have the adequate infrastructure, it can be placed on the cloud. For larger companies, it is based on a subscription-based service. A unique feature of the platform is our analytics concierge. This allows for a ‘wingman’ approach to help our clients if they are in need of assistance when analyzing their data.

How does Pharmafusion differentiate its platform from other systems currently on the market?

Our differentiation has been built from the ground up with a team that really knows the pharmaceutical business. It is based on an award-winning design; it is plug and play and specific to the pharmaceutical industry. It is pre-built with over 50 subject areas that are integrated into a 360 degree view of pharma operations. This integration is the essence of Pharmafusion 360 and helps address the myopic decision making prevalent in the pharma industry. The end result is that everyone is looking at the same data and can understand the impact of business decisions across the entire organization. 

Given the general conservatism towards the uptake of technology in the pharmaceutical industry, how have you seen this change over the past two years?

In our everyday lives, the uptake of technology is very fast. Although the pharma industry has been relatively slow in its uptake, this began to change in 2017. It has definitely turned in the past year, and we are now seeing a far greater confidence in what data analytics and technology can do for a company’s operations. There has definitely been an evolution in how the industry looks at technology and the approach in housing data in the cloud.

How would you like Pharmafusion to be perceived by the market?

We have an innovative platform that was completely built from the ground up, is non-invasive and tremendously flexible. One of our challenges is getting companies to actually experience the platform. What we are trying to do is bring analytics and business intelligence onto a simple dashboard that looks like a TV screen. It is smart TV for pharmaceutical analytics operations, and once our customers have experienced the platform, they have an ‘ah-ha’ moment of what it can do for their business. For us, as we have grown over the past few years, we have found that the flexibility of the platform means it has been an easy process to scale. Being recognized as a top 10 analytics solution providers by Pharma Tech Outlook is testament to the ease of the platform.

What is your longer-term vision for Pharmafusion?

Our long-term vision for Pharmafusion is to be the gold standard for pharmaceutical analytics and to build the best pharmaceutical analytics platform out there for pharmaceutical companies of all sizes and at all stages of commercialization.  We want Pharmafusion to be the go-to for all pharmaceutical analytics.

INTERVIEWS MORE INTERVIEWS

"NORCAT is the only innovation centre in the world that has an operating mine designed to enable start-ups, SMEs, and international companies to develop, test and demonstrate emerging technologies."
"The energy transition can only be funded by big oil, as they are the only players who can balance the low returns of renewables projects with their high earning fossil fuel projects."
"Our commitment to being OEM and technology agnostic sets us apart, enabling collaboration with diverse technologies."
"Wyoming is strategically positioned to address the geopolitical challenges affecting critical minerals, particularly in the uranium sector."

RECENT PUBLICATIONS

Mexico Chemicals 2024

In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.

MORE PREVIOUSLY PUBLISHED

MACIG

"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."

SUBSCRIBE TO OUR NEWSLETTER